scispace - formally typeset
Open AccessJournal ArticleDOI

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, +116 more
- 28 Oct 2017 - 
- Vol. 390, Iss: 10106, pp 1949-1961
TLDR
This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
About
This article is published in The Lancet.The article was published on 2017-10-28 and is currently open access. It has received 1139 citations till now. The article focuses on the topics: Rucaparib & Recurrent Ovarian Carcinoma.

read more

Citations
More filters
Journal ArticleDOI

Applications of Next Generation Sequencing to the Analysis of Familial Breast/Ovarian Cancer.

TL;DR: This review summarizes and discusses the state of the art applications of NGS gene panels, WES and WGS in the context of familial breast/ovarian cancer.
Journal ArticleDOI

Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology

TL;DR: In this article, the authors summarized the current knowledge of the immune environment of endometrial cancer, both for MMRd and MMRp tumors, and discussed the next steps of development for immunotherapy, including various ICI-based combinations planned to limit resistance to immunotherapy.
Journal ArticleDOI

Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study

TL;DR: SCS increases TFST and PRS in PSROC patients with BRCAmut candidate for olaparib maintenance after platinum-based chemotherapy, and indication to SCS should be individualized.
Journal ArticleDOI

PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.

TL;DR: The currently available evidence regarding the use of PARP inhibitors for the treatment of patients with breast and ovarian cancer is reviewed, with a particular focus on the inclusion of older adults in clinical trials of these therapies.
Journal ArticleDOI

Major clinical research advances in gynecologic cancer in 2017

TL;DR: In 2017, 10 topics were selected as major clinical research advances in gynecologic oncology, including poly(ADP-ribose) polymerases inhibitors and immunotherapy, and potential practice changers covered were lymphadenectomy in advanced disease, secondary cytoreductive surgery in recurrent disease, weekly dose-dense regimen for first-line chemotherapy, and effect of platinum-free interval prolongation.
References
More filters
Journal ArticleDOI

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

TL;DR: Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer amongThose receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity.
Journal ArticleDOI

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Eric Pujade-Lauraine, +110 more
- 01 Sep 2017 - 
TL;DR: Olaparib tablet maintenance treatment provided a significant progression-free survival improvement with no detrimental effect on quality of life in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation.
Related Papers (5)

Integrated genomic analyses of ovarian carcinoma

Debra A. Bell, +285 more
- 30 Jun 2011 -